Literature DB >> 3981766

A case-control study of caffeine and methylxanthines in benign breast disease.

F Lubin, E Ron, Y Wax, M Black, M Funaro, A Shitrit.   

Abstract

A dietary case-control study of 854 histologically diagnosed cases of benign breast disease (BBD), 755 matched surgical controls, and 723 matched neighborhood controls was conducted in Israel between 1977 and 1980. No association between coffee consumption and BBD was found. Analyses by histological type, degree of ductal atypia, age, sex, and ethnic origin, controlling for several confounding factors, confirmed the lack of association. The estimated mean intake of methylxanthines was also similar for cases and controls (302, 312, and 313 mg for cases, surgical controls, and neighborhood controls, respectively). No evidence of a dose-response was noted. Our results suggest that there is no association between coffee or methylxanthine consumption and BBD, although we had a 70% chance of finding a risk ratio of 1.5 with an error of 5%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981766

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

Review 1.  Caffeine and health.

Authors:  C H Ashton
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

2.  Caffeine inhibits development of benign mammary gland tumors in carcinogen-treated female Sprague-Dawley rats.

Authors:  D M Wolfrom; A R Rao; C W Welsch
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

Review 3.  Selected health and behavioral effects related to the use of caffeine.

Authors:  R J Lamarine
Journal:  J Community Health       Date:  1994-12

Review 4.  Nonendocrine theories of the etiology of benign breast disease.

Authors:  J P Minton; H Abou-Issa
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

Review 5.  Updates on Nutraceutical Sleep Therapeutics and Investigational Research.

Authors:  Michael Yurcheshen; Martin Seehuus; Wilfred Pigeon
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-21       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.